FDA Clears Emerging AI Software for Brain MRI
The artificial intelligence (AI)-powered software VUNO Med-DeepBrain reportedly automates brain MRI segmentation and provides access to volumetric data on over 100 regions of the brain.
Offering a potentially time-saving antidote to manual identification and quantification of brain structures on magnetic resonance imaging (MRI), the VUNO Med®-DeepBrain® artificial intelligence (AI) software has garnered 510(k) clearance from the Food and Drug Administration (FDA).
VUNO, the developer of the software, said that in addition to white matter hyperintensity and cortical thickness assessments, VUNO Med-DeepBrain offers access to volumetric information on over 100 brain regions.
Offering quantifiable brain data in a customizable report, VUNO Med-DeepBrain may also facilitate earlier diagnosis in cases involving dementia or other neurodegenerative conditions. In study findings presented at the recent Alzheimer’s Association International Conference (AAIC), researchers found that VUNO Med-DeepBrain can predict amyloid positivity in patients with subjective cognitive decline, according to VUNO.
“With this product, we will make every effort to help improve the declining quality of life experienced by many dementia patients,” added Yeha Lee, the CEO of VUNO.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
